|
|
| (4 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #REDIRECT [[Dicyclomine]] |
| |authorTag={{AV}}
| |
| |genericName=dicycloverine
| |
| |aOrAn=a
| |
| |drugClass=[[cholinergic]] antagonist and a [[muscarinic]] antagonist
| |
| |indicationType=treatment
| |
| |indication=functional bowel/[[irritable bowel syndrome]]
| |
| |adverseReactions=[[Dry Mouth]],[[Dizziness]] and [[Blurred Vision]]
| |
| |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
| |
| | |
| * Content
| |
| | |
| <!--Adult Indications and Dosage-->
| |
| | |
| <!--FDA-Labeled Indications and Dosage (Adult)-->
| |
| |fdaLIADAdult======Condition1=====
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition2=====
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition3=====
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition4=====
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| <!--Off-Label Use and Dosage (Adult)-->
| |
| | |
| <!--Guideline-Supported Use (Adult)-->
| |
| |offLabelAdultGuideSupport======Condition1=====
| |
| | |
| * Developed by:
| |
| | |
| * Class of Recommendation:
| |
| | |
| * Strength of Evidence:
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition2=====
| |
| | |
| There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| |
| | |
| <!--Non–Guideline-Supported Use (Adult)-->
| |
| |offLabelAdultNoGuideSupport======Condition1=====
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition2=====
| |
| | |
| There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| |
| | |
| <!--Pediatric Indications and Dosage-->
| |
| | |
| <!--FDA-Labeled Indications and Dosage (Pediatric)-->
| |
| |fdaLIADPed======Condition1=====
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition2=====
| |
| | |
| There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
| |
| | |
| <!--Off-Label Use and Dosage (Pediatric)-->
| |
| | |
| <!--Guideline-Supported Use (Pediatric)-->
| |
| |offLabelPedGuideSupport======Condition1=====
| |
| | |
| * Developed by:
| |
| | |
| * Class of Recommendation:
| |
| | |
| * Strength of Evidence:
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition2=====
| |
| | |
| There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
| |
| | |
| <!--Non–Guideline-Supported Use (Pediatric)-->
| |
| |offLabelPedNoGuideSupport======Condition1=====
| |
| | |
| * Dosing Information
| |
| | |
| :* Dosage
| |
| | |
| =====Condition2=====
| |
| | |
| There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
| |
| | |
| <!--Contraindications-->
| |
| |contraindications=* Condition1
| |
| | |
| <!--Warnings-->
| |
| |warnings=* Description
| |
| | |
| ====Precautions====
| |
| | |
| * Description
| |
| | |
| <!--Adverse Reactions-->
| |
| | |
| <!--Clinical Trials Experience-->
| |
| |clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
| |
| | |
| =====Body as a Whole=====
| |
| | |
| | |
| | |
| | |
| =====Cardiovascular=====
| |
| | |
| | |
| | |
| | |
| =====Digestive=====
| |
| | |
| | |
| | |
| | |
| =====Endocrine=====
| |
| | |
| | |
| | |
| | |
| =====Hematologic and Lymphatic=====
| |
| | |
| | |
| | |
| | |
| =====Metabolic and Nutritional=====
| |
| | |
| | |
| | |
| | |
| =====Musculoskeletal=====
| |
| | |
| | |
| | |
| | |
| =====Neurologic=====
| |
| | |
| | |
| | |
| | |
| =====Respiratory=====
| |
| | |
| | |
| | |
| | |
| =====Skin and Hypersensitivy Reactions=====
| |
| | |
| | |
| | |
| | |
| =====Special Senses=====
| |
| | |
| | |
| | |
| | |
| =====Urogenital=====
| |
| | |
| | |
| | |
| | |
| =====Miscellaneous=====
| |
| | |
| | |
| | |
| <!--Postmarketing Experience-->
| |
| |postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
| |
| | |
| =====Body as a Whole=====
| |
| | |
| | |
| | |
| =====Cardiovascular=====
| |
| | |
| | |
| | |
| =====Digestive=====
| |
| | |
| | |
| | |
| =====Endocrine=====
| |
| | |
| | |
| | |
| =====Hematologic and Lymphatic=====
| |
| | |
| | |
| | |
| =====Metabolic and Nutritional=====
| |
| | |
| | |
| | |
| =====Musculoskeletal=====
| |
| | |
| | |
| | |
| =====Neurologic=====
| |
| | |
| | |
| | |
| =====Respiratory=====
| |
| | |
| | |
| | |
| =====Skin and Hypersensitivy Reactions=====
| |
| | |
| | |
| | |
| =====Special Senses=====
| |
| | |
| | |
| | |
| =====Urogenital=====
| |
| | |
| | |
| | |
| =====Miscellaneous=====
| |
| | |
| | |
| | |
| <!--Drug Interactions-->
| |
| |drugInteractions=* Drug
| |
| :* Description
| |
| | |
| <!--Use in Specific Populations-->
| |
| |useInPregnancyFDA=* '''Pregnancy Category'''
| |
| |useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
| |
| | |
| There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
| |
| |useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
| |
| |useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
| |
| |useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
| |
| |useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
| |
| |useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
| |
| |useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
| |
| |useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
| |
| |useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
| |
| |useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
| |
| |useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
| |
| | |
| <!--Administration and Monitoring-->
| |
| |administration=* Oral
| |
| | |
| * Intravenous
| |
| |monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
| |
| | |
| * Description
| |
| | |
| <!--IV Compatibility-->
| |
| |IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Overdosage-->
| |
| |overdose====Acute Overdose===
| |
| | |
| ====Signs and Symptoms====
| |
| | |
| * Description
| |
| | |
| ====Management====
| |
| | |
| * Description
| |
| | |
| ===Chronic Overdose===
| |
| | |
| There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Pharmacology-->
| |
| | |
| <!--Drug box 2-->
| |
| |drugBox=<!--Mechanism of Action-->
| |
| |mechAction=*
| |
| | |
| <!--Structure-->
| |
| |structure=*
| |
| | |
| : [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
| |
| | |
| <!--Pharmacodynamics-->
| |
| |PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Pharmacokinetics-->
| |
| |PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Nonclinical Toxicology-->
| |
| |nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Clinical Studies-->
| |
| |clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--How Supplied-->
| |
| |howSupplied=*
| |
| |packLabel=<!--Patient Counseling Information-->
| |
| |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Precautions with Alcohol-->
| |
| |alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
| |
| | |
| <!--Brand Names-->
| |
| |brandNames=* ®<ref>{{Cite web | title = | url = }}</ref>
| |
| | |
| <!--Look-Alike Drug Names-->
| |
| |lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher = | date = }}</ref>
| |
| | |
| <!--Drug Shortage Status-->
| |
| |drugShortage=
| |
| }}
| |
| {{PillImage
| |
| |fileName=No image.jpg
| |
| }}
| |
| {{LabelImage
| |
| |fileName={{PAGENAME}}11.png
| |
| }}
| |
| {{LabelImage
| |
| |fileName={{PAGENAME}}11.png
| |
| }}
| |
| <!--Pill Image-->
| |
| | |
| | |
| | |
| <!--Label Display Image-->
| |
| | |
| | |
| | |
| | |
| | |
| <!--Category-->
| |
| | |
| [[Category:Drug]]{{drugbox | |
| | IUPAC_name = 2-diethylaminoethyl1- cyclohexylcyclohexane- 1-carboxylate
| |
| | image = dicyclomine-trans.png
| |
| | CAS_number = 77-19-0
| |
| | ATC_prefix = A03
| |
| | ATC_suffix = AA07
| |
| | ATC_supplemental =
| |
| | PubChem = 3042
| |
| | DrugBank = APRD00113
| |
| | C=19 | H=35 | N=1 | O=2
| |
| | molecular_weight = 309.487 g/mol
| |
| | bioavailability =
| |
| | protein_bound = >99%
| |
| | metabolism =
| |
| | elimination_half-life =
| |
| | excretion =
| |
| | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| |
| | pregnancy_US = <!-- A / B / C / D / X -->
| |
| | pregnancy_category =
| |
| | legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| |
| | legal_UK = <!-- GSL / P / POM / CD -->
| |
| | legal_US = <!-- OTC / Rx-only -->
| |
| | legal_status =
| |
| | routes_of_administration =
| |
| }}
| |
| '''Dicyclomine''' is an [[anticholinergic]] that blocks [[muscarinic acetylcholine receptor|muscarinic receptors]]. Dicyclomine is known as dicycloverine hydrochloride in the UK.
| |
| | |
| ==Clinical uses==
| |
| Dicyclomine is used to treat [[intestinal hypermotility]], the symptoms of [[Irritable Bowel Syndrome]] (IBS) (also known as spastic colon). It relieves muscle spasms in the gastrointestinal tract by blocking the activity of a certain natural substance in the body. It is a smooth muscle relaxer.
| |
| | |
| In America, it is sold under the trade names: Bentyl, Byclomine, Dibent, Di-Spaz, Dilomine.
| |
| | |
| It is sold under the trade names Bentylol (Hoechst Marion Roussel), Formulex (ICN), and Lomine (Riva) in Canada.
| |
| | |
| ==Sources==
| |
| *Brenner, G. M. (2000). ''Pharmacology.'' Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
| |
| *Canadian Pharmacists Association (2000). ''Compendium of Pharmaceuticals and Specialties'' (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4
| |
| | |
| ==External links==
| |
| * [http://www.medicinenet.com/dicyclomine/article.htm Dicyclomine] on Medicine Net
| |
| * [http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a684007.html Dicyclomine] on Medline Plus
| |
| | |
| {{Drugs for functional gastrointestinal disorders }}
| |
| [[Category:Muscarinic antagonists]]
| |